Structures by: Skelton J. M.
Total: 79
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=25.058(5)Å b=14.038(3)Å c=18.102(4)Å
α=90.00° β=97.313(3)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=24.641(4)Å b=13.7018(6)Å c=17.5317(9)Å
α=90.00° β=97.572(8)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=24.7872(11)Å b=13.8653(8)Å c=17.7857(13)Å
α=90.00° β=97.493(4)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=24.290(5)Å b=13.584(3)Å c=17.379(4)Å
α=90.00° β=98.51(3)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=24.215(5)Å b=13.516(3)Å c=17.266(4)Å
α=90.00° β=98.70(3)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
0.5(C48H84Au6N18)
IUCrJ (2016) 3, 5
a=23.765(5)Å b=13.396(3)Å c=16.789(3)Å
α=90.00° β=99.58(3)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
0.25(C48H84Au6N18)
IUCrJ (2016) 3, 5
a=26.529(5)Å b=13.396(3)Å c=31.094(6)Å
α=90.00° β=110.11(3)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
0.5(C48H84Au6N18)
IUCrJ (2016) 3, 5
a=37.163(7)Å b=13.417(3)Å c=30.421(6)Å
α=90.00° β=88.48(3)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=23.7794(13)Å b=14.0552(6)Å c=20.087(2)Å
α=90.00° β=121.333(10)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=24.316(4)Å b=14.341(2)Å c=20.951(5)Å
α=90.00° β=121.105(2)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=23.6575(13)Å b=13.9552(6)Å c=19.838(4)Å
α=90.00° β=121.445(6)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=23.5723(13)Å b=13.8758(6)Å c=19.647(4)Å
α=90.00° β=121.589(6)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=23.4383(14)Å b=13.7533(6)Å c=19.341(4)Å
α=90.00° β=121.812(6)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=23.4449(14)Å b=13.6963(7)Å c=19.285(2)Å
α=90.00° β=121.920(10)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=23.3640(12)Å b=13.6258(7)Å c=19.112(2)Å
α=90.00° β=122.080(9)° γ=90.00°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H42Au3N9
IUCrJ (2016) 3, 5
a=23.3195(10)Å b=13.5632(7)Å c=18.951(3)Å
α=90.00° β=122.188(7)° γ=90.00°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.0907(3)Å b=11.5779(4)Å c=22.8104(7)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1349(3)Å b=11.6868(4)Å c=22.8660(8)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.0963(2)Å b=11.5574(3)Å c=22.8612(7)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1445(3)Å b=11.7130(3)Å c=22.8862(5)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1415(4)Å b=11.7002(4)Å c=22.8837(6)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1357(3)Å b=11.6782(3)Å c=22.8834(6)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1405(3)Å b=11.6923(2)Å c=22.8838(4)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1280(3)Å b=11.6579(3)Å c=22.8759(5)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1311(3)Å b=11.6667(2)Å c=22.8800(4)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1237(2)Å b=11.6442(2)Å c=22.8738(4)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1200(3)Å b=11.6339(3)Å c=22.8697(4)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1158(2)Å b=11.6222(2)Å c=22.8715(3)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1066(2)Å b=11.5983(2)Å c=22.8627(3)Å
α=90.00° β=90.00° γ=90.00°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1070(3)Å b=11.5902(3)Å c=22.8593(6)Å
α=90.00° β=90.00° γ=90.00°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1064(3)Å b=11.5845(3)Å c=22.8569(6)Å
α=90.00° β=90.00° γ=90.00°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1048(3)Å b=11.5802(3)Å c=22.8576(6)Å
α=90.00° β=90.00° γ=90.00°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.0992(4)Å b=11.5635(3)Å c=22.8525(6)Å
α=90.00° β=90.00° γ=90.00°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.0972(2)Å b=11.5751(2)Å c=22.8531(3)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.0881(3)Å b=11.5538(2)Å c=22.8478(3)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.0823(3)Å b=11.5422(2)Å c=22.8439(3)Å
α=90.00° β=90.00° γ=90.00°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1228(4)Å b=11.6522(6)Å c=22.8488(10)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.1074(3)Å b=11.6193(5)Å c=22.8456(9)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.0885(6)Å b=11.5482(7)Å c=22.7898(12)Å
α=90° β=90° γ=90°
C11H12N4O2S
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.4973(2)Å b=8.21180(10)Å c=21.9658(3)Å
α=90° β=90° γ=90°
C11H12N4O2S
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.5008(2)Å b=8.21410(10)Å c=21.9821(4)Å
α=90° β=90° γ=90°
C11H12N4O2S
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.49500(10)Å b=8.20940(10)Å c=21.9489(3)Å
α=90° β=90° γ=90°
C11H12N4O2S
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.49140(10)Å b=8.20690(10)Å c=21.9332(3)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.48840(10)Å b=8.20480(10)Å c=21.9167(3)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.48520(10)Å b=8.20200(10)Å c=21.9002(3)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.48140(10)Å b=8.19930(10)Å c=21.8844(3)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.47950(10)Å b=8.19740(10)Å c=21.8693(3)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.4763(2)Å b=8.19460(10)Å c=21.8522(4)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.47010(10)Å b=8.18890(10)Å c=21.8216(4)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.47340(10)Å b=8.19210(10)Å c=21.8397(3)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.46660(10)Å b=8.18680(10)Å c=21.8103(2)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.45970(10)Å b=8.18020(10)Å c=21.7812(2)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.4902(9)Å b=8.2249(6)Å c=22.0106(14)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.45880(10)Å b=8.18000(10)Å c=21.7664(2)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.4899(5)Å b=8.2086(4)Å c=21.9106(9)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.4829(6)Å b=8.1938(3)Å c=21.8441(9)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.4687(6)Å b=8.1829(9)Å c=21.8084(4)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.4393(7)Å b=8.1764(4)Å c=21.7395(13)Å
α=90.00° β=90.00° γ=90.00°
4-bromo-2-methylanilinium 3,5-dinitrobenzoate
C7N1Br1H91,C7N2O6H31
CrystEngComm (2019) 21, 10 1626
a=10.4081(4)Å b=5.8338(2)Å c=13.2672(5)Å
α=90° β=107.035(4)° γ=90°
4-chloro-2-methylanilinium 3,5-dinitrobenzoate
C7N1Cl1H91,C7N2O6H31
CrystEngComm (2019) 21, 10 1626
a=10.2583(6)Å b=5.8537(3)Å c=13.2818(9)Å
α=90° β=106.933(7)° γ=90°
4-iodoaniline 3,5-dinitrobenzoic acid
C6N1I1H6,C7N2O6H4
CrystEngComm (2019) 21, 10 1626
a=7.2766(3)Å b=7.3862(3)Å c=14.2883(5)Å
α=99.348(3)° β=103.715(4)° γ=90.271(3)°
4-iodoanilinium 3,5-dinitrobenzoate
C6N1I1H71,C7N2O6H31
CrystEngComm (2019) 21, 10 1626
a=6.75880(10)Å b=12.0929(2)Å c=36.4619(5)Å
α=90° β=90° γ=90°
4-bromo-2-methylaniline 3,5-dinitrobenzoic acid
C7N1Br1H8,C7N2O6H4
CrystEngComm (2019) 21, 10 1626
a=7.1802(4)Å b=7.2420(4)Å c=14.7292(6)Å
α=87.048(4)° β=88.078(4)° γ=89.926(5)°
4-bromoanilinium 3,5-dinitrobenzoate
C6N1Br1H71,C7N2O6H31
CrystEngComm (2019) 21, 10 1626
a=6.79370(10)Å b=11.95740(10)Å c=35.8729(3)Å
α=90° β=90° γ=90°
4-bromoaniline 3,5-dinitrobenzoic acid
C6N1Br1H6,C7N2O6H4
CrystEngComm (2019) 21, 10 1626
a=7.3332(10)Å b=13.937(2)Å c=15.611(2)Å
α=65.133(5)° β=82.758(6)° γ=83.330(6)°
Lawsone-bipyridyl
2(C10H6O3),C10H8N2
CrystEngComm (2015) 17, 40 7684
a=10.6360(3)Å b=4.7798(1)Å c=23.0987(9)Å
α=90.00° β=96.131(2)° γ=90.00°
Lawsone-ethylenebipyridine
C12H12N22,2(C10H5O31)
CrystEngComm (2015) 17, 40 7684
a=3.8157(1)Å b=28.0772(7)Å c=11.2326(3)Å
α=90.00° β=96.542(2)° γ=90.00°
Lawsone-trimethylenebipyridine
C13H14N2,2(C10H6O3)
CrystEngComm (2015) 17, 40 7684
a=22.5402(9)Å b=50.511(2)Å c=4.6451(2)Å
α=90.00° β=90.00° γ=90.00°
Lawsone-hydroxypyridine
C15H11NO4
CrystEngComm (2015) 17, 40 7684
a=13.6937(12)Å b=5.1534(3)Å c=17.5288(12)Å
α=90° β=92.329(7)° γ=90°
Tris(3,5-diisopropyl-1,2,4-triazolato-N,N)-tri-gold(I)
C24H41Au3N9,C24H42
IUCrJ (2016) 3, 5
a=23.3975(14)Å b=13.3010(11)Å c=16.1373(15)Å
α=90.00° β=99.901(6)° γ=90.00°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=9.0785(2)Å b=11.5265(3)Å c=22.8581(6)Å
α=90° β=90° γ=90°
C11H12N4O2S
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.5040(2)Å b=8.21620(10)Å c=21.9984(4)Å
α=90° β=90° γ=90°
Sulfamerazine
C11H12N4O2S
Molecular Pharmaceutics (2015) 12, 3735-3748
a=14.46380(10)Å b=8.18350(10)Å c=21.7953(2)Å
α=90° β=90° γ=90°
C52H78N2P4Pt2
C52H78N2P4Pt2
Inorganic chemistry (2016) 55, 21 10955-10967
a=8.9899(3)Å b=9.6169(3)Å c=15.8333(7)Å
α=92.353(3)° β=93.954(3)° γ=94.633(3)°
C52H78N2P4Pt2
C52H78N2P4Pt2
Inorganic chemistry (2016) 55, 21 10955-10967
a=18.7794(4)Å b=10.5232(2)Å c=14.8114(3)Å
α=90° β=110.929(3)° γ=90°
C22H25NSi2
C22H25NSi2
Inorganic chemistry (2016) 55, 13 6465-6480
a=6.1804(2)Å b=10.9724(4)Å c=16.4113(5)Å
α=90.00° β=90.271(2)° γ=90.00°
C22H25NSi2
C22H25NSi2
Inorganic chemistry (2016) 55, 13 6465-6480
a=6.3292(2)Å b=7.7163(3)Å c=43.8439(17)Å
α=90.00° β=90.00° γ=90.00°
C52H70N2P2Pt
C52H70N2P2Pt
Inorganic chemistry (2016) 55, 13 6465-6480
a=9.5643(3)Å b=10.5536(4)Å c=11.9787(4)Å
α=78.149(3)° β=81.742(3)° γ=78.372(3)°
H04prr13
C52H77NP4Pt2,CH4O
Inorganic chemistry (2016) 55, 13 6465-6480
a=21.0064(3)Å b=8.32680(10)Å c=30.8889(4)Å
α=90° β=92.0580(10)° γ=90°